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Abstract
Background: Epithelial ovarian carcinoma is a significant cause of cancer mortality in women worldwide and in the United
States. Epithelial ovarian cancer comprises several histological subtypes, each with distinct clinical and molecular
characteristics. The natural history of this heterogeneous disease, including the cell types of origin, is poorly understood.
This study applied recently developed methods for high-throughput DNA methylation profiling to characterize ovarian
cancer cell lines and tumors, including representatives of three major histologies.
Methodology/Principal Findings: We obtained DNA methylation profiles of 1,505 CpG sites (808 genes) in 27 primary
epithelial ovarian tumors and 15 ovarian cancer cell lines. We found that the DNA methylation profiles of ovarian cancer cell
lines were markedly different from those of primary ovarian tumors. Aggregate DNA methylation levels of the assayed CpG
sites tended to be higher in ovarian cancer cell lines relative to ovarian tumors. Within the primary tumors, those of the
same histological type were more alike in their methylation profiles than those of different subtypes. Supervised analyses
identified 90 CpG sites (68 genes) that exhibited ‘subtype-specific’ DNA methylation patterns (FDR,1%) among the tumors.
In ovarian cancer cell lines, we estimated that for at least 27% of analyzed autosomal CpG sites, increases in methylation
were accompanied by decreases in transcription of the associated gene.
Significance: The significant difference in DNA methylation profiles between ovarian cancer cell lines and tumors
underscores the need to be cautious in using cell lines as tumor models for molecular studies of ovarian cancer and other
cancers. Similarly, the distinct methylation profiles of the different histological types of ovarian tumors reinforces the need
to treat the different histologies of ovarian cancer as different diseases, both clinically and in biomarker studies. These data
provide a useful resource for future studies, including those of potential tumor progenitor cells, which may help illuminate
the etiology and natural history of these cancers.
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Introduction
Ovarian cancer is the leading cause of death among all
gynecological cancers in the United States [1], and is the sixth
leading cause of all cancer deaths among women. There are four
major histological types of ovarian cancer (serous, endometrioid,
mucinous, and clear cell), each with distinct histopathological,
clinical and molecular characteristics. The natural history of
ovarian tumors, including their cell type of origin and steps of
carcinogenesis, is poorly understood and has been the subject of
much debate and discussion. Many studies of ovarian cancer are
based on ovarian cancer derived cell lines, but it is unclear to what
extent these cell lines accurately model the disease with respect to
various molecular characteristics, including DNA methylation
status.
DNA methylation is one of the epigenetic mechanisms that
plays a role in many important biological processes including X-
inactivation [2–4], silencing parasitic DNA elements [5], genomic
imprinting [6], aging [7], male infertility [8], and cancer. Previous
studies have shown CpG island DNA hypermethylation in various
cancers, including ovarian tumors, as well as reduced levels of
global DNA methylation associated with cancer [9–15]. Further-
more, the DNA methylation profile of a tumor cell is a reflection of
its somatic lineage, environmental exposure, genetic predisposi-
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logical advances have enabled quantitative assessment of the DNA
methylation status of thousands of loci at once, providing an
unprecedented opportunity to investigate the epigenetic signature
of a cell. This rich source of information could be utilized to better
understand the cell of origin of the subtypes and the steps of
carcinogenesis, to identify appropriate model systems for future
studies, and to discover candidate biomarkers for disease
detection, classification, and monitoring.
Results
DNA Methylation Profiles of Ovarian Surface Epithelial
Primary Tumors and Cell Lines
We assessed the DNA methylation profile of 1,505 CpG sites
(associated with 808 genes) in 15 ovarian cell lines and 27 primary
tumors (15 serous, 9 endometrioid, and 3 clear cell), using the
Illumina GoldenGate Cancer Panel I [16] (see Supplemental File
S1 for methylation array details). This panel has been used in
several previous studies by others and us [8,16–22]. Several
investigators have validated the DNA methylation results of this
panel by pyrosequencing [17,19], Methylation Sensitive PCR
(MSP) [16,21], and bisulfite genomic sequencing [16]. The
reproducibility of this assay has also been reported previously
[16,19]. The clinical and histopathological characteristics of the
tumors and cell lines are detailed in Tables 1 and 2 respectively.
Of the 1,505 CpG sites (808 genes) surveyed, 1,184 sites (686
genes) exhibited sufficient variation across the 42 specimens for
further analysis (see Methods). Unsupervised hierarchical cluster-
ing of both specimens and CpG sites using these 1,184 probes is
shown in Figure 1. The primary division in the clustering of the
specimens was between cell lines and tumors, each of which
formed a distinct cluster. Among the tumors, the primary serous
and endometrioid tumors each formed a distinct cluster (with one
exception), whereas the three clear cell tumors were distributed
between the two main clusters. There was no clear pattern of sub-
clustering among the cell lines, despite the diversity of histological
types nominally represented. The most notable cluster of CpG
sites was a large group of CpG sites on the X chromosome with
highly correlated methylation levels across all specimens. Because
of the special role of DNA methylation on the X chromosome in
dosage compensation, we excluded X-linked genes from further
Table 1. Histology and clinical characteristics of primary ovarian tumors.
Tumor No. Histology Stage PatientAge CA125 (U/mL) Menopausal Status Elevated Risk
CC-T1 Clear Cell IA 51 25 Peri N
CC-T2 Clear Cell IC 58 24 Post N
CC-T3 Clear Cell IC 45 705 Peri N
E-T1 Endometrioid IIIC 75 112 Post N
E-T2 Endometrioid IIB 43 207 Pre N
E-T3 Endometrioid IIIC 58 2662 Post Y
E-T4 Endometrioid IIA 58 75 Post Y
E-T5 Endometrioid IA 55 372 Post N
E-T6 Endometrioid IB 46 3897 Peri N
E-T7 Endometrioid IB 47 5201 Post N
E-T8 Endometrioid IC 38 1720 Post Y
E-T9 Endometrioid IIIB 51 2301 Post N
S-T1 Serous IIIC 82 134 Post N
S-T2 Serous IVA 58 6706 Post N
S-T3 Serous IIIC 77 1828 Post N
S-T4 Serous IIIC 74 994 Post N
S-T5 Serous IIIC 43 480 Pre N
S-T6 Serous IIIC 70 1504 Post N
S-T7 Serous IIIC 74 1023 Post Y
S-T8 Serous IIIC 56 396 Post N
S-T9 Serous IIIC 69 835 Post N
S-T10 Serous IIIC 59 4626 Post N
S-T11 Serous IIIC 48 12 Post Y
S-T12 Serous IIIC 68 49 Post N
S-T13 Serous IIIC 49 195 Peri N
S-T14 Serous IIIC 42 1075 Pre N
S-T15 Serous IIIC 49 8000 Post N
Menopausal Status was recorded as follows: Post = age.= 55 or self-reported menopause, hormone replacement therapy, hysterectomy or oophorectomy; Peri =
age,55 and inconsistent menstruation; Pre = age,55 and menstruating (See Appendix S1). Elevated Risk was recorded as follows: Y if one or more of the following
conditions were met: a) family history of ovarian or breast cancer; b) Ashkenazi Jewish ethnicity and family history of breast cancer; c) BRCA1 or 2 mutation; d) mutation
status unknown and family history of BRCA1 or 2 mutation [64].
doi:10.1371/journal.pone.0009359.t001
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representing different CpG sites associated with the same gene
tended to be highly correlated (mean r value: 0.64 for related pairs
of probes and 0.04 for unrelated pairs; see Figures S1 and S2).
We further explored differences in DNA methylation between
cell lines and tumors, using a two-sample t-test to compare DNA
methylation levels of selected CpG sites. Only the 1,110 CpG sites
that met a minimal level of variability in methylation levels across
these specimens (see Methods) were included in this analysis. We
thus identified 489 CpG sites (associated with 337 genes) that varied
significantly in DNA methylation level between the ovarian cancer
derived cell lines and the primary ovarian cancer tumors at a false
discovery rate (FDR) less than 1% [23] (see Figure 2 and
Supplemental File S2). Among CpG sites whose mean methylation
levels differed between cell lines and tumors, the vast majority were
more highly methylated in the cell lines (445 of 489 CpG sites, 299
of 337 genes). The proposed cell of origin of ovarian carcinoma
(Ovarian Surface Epithelium) is currently under debate [24]. Whole
ovary, which is comprised of various cell types, including granulosa
andfollicularcells,isnot anappropriatecontrol.Onthe otherhand,
the normal cells that contaminate tumor samples include blood
cells. Therefore, we compared DNA methylation levels in
leukocytes (obtained from buffy coat) from two healthy females
(age.60). The inclusion of leukocytes could also serve as a first step
to assess the feasibility of blood-based biomarker development. For
the majority of probes, DNA methylation levels in the leukocytes
were similar to those observed in the tumor samples (see Figure 2).
The elevated levels of DNA methylation in the leukocytes among
the CpG sites that had elevated methylation in tumors relative to
cell lines was particularly striking. The 39 CpG sites (associated with
35 genes) whose methylation levels differed most significantly
between cell lines from tumors (FDR,0.1%) and had the largest
differencesin mean methylation levels between cell lines and tumors
are shown in Table 3.
To explore differences in DNA methylation profiles between
tumor histologies, we compared the DNA methylation levels of 818
autosomal CpG sites selected for variability in DNA methylation
levels across the tumors (see Methods). We applied a two-sample t-
test to compare pairs of tumor histologies, and adjusted for multiple
comparisons by controlling the false discovery rate [23] (see
Methods for details). In this way, we identified 90 CpG sites (68
genes) that showed significant differences in methylation levels
between at least one pair of tumor histologies at an FDR,1% (see
Figure 3, Supplemental File S2). Note that a small fraction of the
CpG sites with ‘subtype-specific’ DNA methylation were identified
in more than one pairwise comparison (11 of 90 CpG sites; 12 of 68
genes). Serous and endometrioid tumors were distinguished by the
largest number of CpG sites (70 CpG sites, 52 genes), of which 49
CpG sites (36 genes) were more highly methylated on average in
endometrioid tumors. Nineteen CpG sites (18 genes) and 12 CpG
sites (10 genes) differed significantly in mean methylation between
clear cell and serous tumors, or clear cell and endometrioid tumors,
respectively. Nearly all of the 26 CpG sites (23 genes) with
differential methylation between clear cell tumors and serous or
endometrioid tumors (or both), were more highly methylated on
average in clear cell tumors (24 of 26 CpG sites, 21 of 23 genes). For
each pairwise comparison, the CpG sites with the most significant
differences in methylation level between the two tumor histologies
are shown in Tables 4, 5 and 6 (see Supplemental Figure S3 for
extent of overlap between CpG sites and genes across lists, and
Supplemental File S3, for CpG island information and distance to
transcription start site for the probes shown in Tables 4, 5 and 6).
Age-associated DNA hypermethylation is a well-established
phenomenon [7]. Therefore, we examined age-associated meth-
ylation changes in the tumor specimens. After adjusting for
histological type and controlling the false discovery rate [23], no
CpG sites showed a significant association with age.
Relationship between Gene Expression and DNA
Methylation Status
To investigate the relationship between DNA methylation status
and gene expression, we measured levels of transcripts from the
same set of genes in the same cell lines and primary tumors, using
HEEBO, a 70mer oligonucleotide DNA microarray [25]. We
Table 2. Characteristics of ovarian cancer cell lines.
Cell Line Histology Derivation Notes Ref. Source
2008 Serous unknown - serous - stage IV [65] Dr. George Coukos (Abramson Family Cancer Research Institute
at University of Pennsylvania)
A1847 Adenocarcinoma unknown [66] Dr. Ingegerd Hellstro ¨m (University of Washington, Seattle)
A2780 Adenocarcinoma tumor [67] Dr. Tom Hamilton (Fox Chase Cancer Research Center,
Philadelphia)
CAOV3 Adenocarcinoma tumor ATCC (J. Fogh) American Type Culture Collection (HTB-75)
ES2 Clear Cell tumor - clear cell [68] American Type Culture Collection (CRL-1978)
IGROV1 Endometrioid tumor - endometrioid - stage III [69] Pacific Ovarian Cancer Research Consortium
HEY Serous tumor - serous [70] Dr. Naoto Ueno (M.D. Anderson Cancer Center)
OVCAR3 Serous ascites - adenocarcinoma [71] Pacific Ovarian Cancer Research Consortium
OVCAR5 Adenocarcinoma tumor [72] Dr. Ingegerd Hellstro ¨m (University of Washington, Seattle)
OVCAR10 Adenocarcinoma tumor [72] Dr. Ingegerd Hellstro ¨m (University of Washington, Seattle)
OV90 Serous ascites - serous - stage IIIC - grade 3 [73] American Type Culture Collection (CRL-11732)
PEO1 Adenocarcinoma ascites - stage III [74] Dr. Ingegerd Hellstro ¨m (University of Washington, Seattle)
SKOV3 Adenocarcinoma ascites [75] American Type Culture Collection (HTB-77)
TOV112D Endometrioid tumor - endometrioid - stage IIIC- grade 3 [73] American Type Culture Collection (CRL-11731)
TOV21G Clear Cell tumor - clear cell - stage III - grade 3 [73] American Type Culture Collection (CRL-11730)
doi:10.1371/journal.pone.0009359.t002
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PLoS ONE | www.plosone.org 3 February 2010 | Volume 5 | Issue 2 | e9359Figure 1. DNA methylation profiles of ovarian cancer cell lines and tumors. DNA methylation profiles for 27 ovarian primary tumors and 15
ovarian cell lines are shown. Only the 1,184 CpG sites (686 genes) with variable DNA methylation levels across these specimens are shown (see
Methods). Methylation values (b-values) were mean centered for each gene (across all specimens) then CpG sites and specimens were hierarchically
clustered. Red indicates high methylation relative to the site-specific mean, green indicates low methylation relative to the mean. Rows of data
corresponding to selected CpG sites (those with the greatest magnitude of difference between tumors and cell lines, or between pairs of tumor
histologies) are indicated to the right of the panel. CL=Cell line, S=Serous tumor, E=Endometrioid tumor, CC=Clear cell tumor.
doi:10.1371/journal.pone.0009359.g001
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case restricted the analysis to autosomal genes selected for
variation in methylation levels across the specimen set (see
Methods). Promoter DNA methylation and levels of the
corresponding gene’s transcript have been found to be inversely
correlated in some cases, but the relationship is not necessarily
linear. Therefore, we used Spearman correlation, rather than
Pearson correlation to examine this relationship for each locus in
each of the two datasets (Figure 4). In cell lines, we found a clear
trend towards a negative correlation between DNA methylation
levels and gene expression for the 828 CpG sites whose
methylation levels varied among the cell lines (Figure 4A, mean
r=20.22). We estimated that for at least 27% of these 828 CpG
sites, increases in methylation were accompanied by decreases in
transcription of the associated gene (Figure 4A). For the tumor
tissue samples, the correlation between DNA methylation levels
and the corresponding transcript abundance, for the 758 CpG
sites with significant variation in methylation across tumors, was
also negative, but much weaker (Figure 4B, mean r=20.08). We
estimated that for at least 16% of these 758 CpG sites, increases in
methylation were accompanied by decreases in transcription of the
associated gene (Figure 4B). As expected, CpG sites at which
methylation was positively correlated with expression of the
corresponding transcript were rare. Indeed, the proportion of
CpG sites exhibiting positive correlation (r.0.5) between
methylation values and expression values was significantly less
than that observed in randomly paired CpG sites (in the data from
ovarian cancer cell lines, approximately 42% fewer than would be
expected if there were no interaction). Scatterplots of DNA
methylation levels versus gene expression levels for the 8 CpG sites
with the strongest negative correlations between these values are
shown in Figure 5A and 5B, for cell lines and tumors, respectively.
Figure 2. Differential DNA methylation between ovarian cell lines and tumors. DNA methylation levels in tumors, cell lines and buffy coat
(leukocytes) are shown for the 489 autosomal CpG sites (337 genes) with significant differences in DNA methylation between cell lines and tumors.
Methylation values (b-values) were mean centered for each gene (across tumor and cell line specimens). Data were hierarchically clustered only for
the CpG sites. The displayed CpG sites were selected based on the adjusted p-values associated with differential expression between tumors and cell
lines. Red indicates high methylation relative to the site-specific mean, green indicates low methylation relative to the mean. Rows of data
corresponding to sites with the greatest magnitude of difference in methylation levels (b-values) between tumors and cell lines are labeled (top 5
sites in each direction). CL= Cell line, S=Serous tumor, E=Endometrioid tumor, CC=Clear cell tumor, BC=Buffy coat.
doi:10.1371/journal.pone.0009359.g002
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transcription of the corresponding gene across the cell lines was
only weakly correlated to the same association across the tumors,
(Pearson r=0.19) (Supplemental Figure S4).
Hypermethylation of CpG dinucleotides located in promoter
59CpG islands has been shown to be associated with gene silencing
[26–29]. We therefore examined the relationship between promoter
DNA hypermethylation and gene expression in the context of CpG
islands (as defined according to either the Takai and Jones criteria
[30] or the Gardiner-Garden criteria [31]). In the cell lines, we found
that the correlation between DNA methylation and gene expression
levels tended to be more strongly negative among CpGs contained
within CpG islands (mean b-values: 20.25 versus 20.12 for loci that
met one or more CpG island criteria (n=585) versus loci that met
Table 3. Loci with differential methylation between ovarian tumors and cell lines.
Gene Symbol Probe ID Cell Line-Tumor (mean b) Cell Lines (mean b) Tumors (mean b)
CL . TUMORS
FES FES_P223_R 0.79 0.87 0.08
FRZB FRZB_E186_R 0.77 0.95 0.19
FES FES_E34_R 0.76 0.84 0.08
KCNK4 KCNK4_E3_F 0.75 0.89 0.14
CRIP1 CRIP1_P874_R 0.75 0.90 0.15
POMC POMC_P400_R 0.75 0.87 0.12
TBX1 TBX1_P885_R 0.72 0.91 0.19
COL1A2 COL1A2_P48_R 0.68 0.88 0.20
FRZB FRZB_P406_F 0.67 0.74 0.06
PYCARD PYCARD_E87_F 0.66 0.75 0.09
PROK2 PROK2_P390_F 0.65 0.66 0.01
ESR2 ESR2_E66_F 0.65 0.66 0.01
DES DES_E228_R 0.64 0.77 0.13
PODXL PODXL_P1341_R 0.63 0.71 0.08
THBS2 THBS2_P605_R 0.62 0.83 0.21
TNFRSF10C TNFRSF10C_E109_F 0.62 0.83 0.21
COL1A2 COL1A2_E299_F 0.61 0.82 0.21
FGF8 FGF8_P473_F 0.61 0.79 0.17
KIT KIT_P367_R 0.60 0.67 0.06
COL1A1 COL1A1_P5_F 0.60 0.74 0.14
TUMORS . CL
PRSS1 PRSS1_P1249_R 20.58 0.23 0.81
PLA2G2A PLA2G2A_P528_F 20.56 0.23 0.79
KIAA0125 KIAA0125_E29_F 20.54 0.19 0.73
CD1A CD1A_P6_F 20.51 0.29 0.80
CXCL9 CXCL9_E268_R 20.45 0.28 0.73
GABRG3 GABRG3_P75_F 20.44 0.38 0.83
PLA2G2A PLA2G2A_E268_F 20.43 0.46 0.89
USP29 USP29_E274_F 20.42 0.44 0.85
CTLA4 CTLA4_P1128_F 20.41 0.41 0.82
GABRG3 GABRG3_E123_R 20.40 0.51 0.92
GML GML_P281_R 20.39 0.45 0.84
PTHR1 PTHR1_P258_F 20.38 0.30 0.68
GNAS GNAS_E58_F 20.34 0.53 0.86
CHI3L2 CHI3L2_P226_F 20.30 0.57 0.86
DSG1 DSG1_P159_R 20.30 0.63 0.92
IL4 IL4_P262_R 20.29 0.61 0.90
BMPR1A BMPR1A_E88_F 20.27 0.57 0.83
LMTK2 LMTK2_P1034_F 20.26 0.51 0.77
The 39 CpG sites (35 genes) with the greatest difference in DNA methylation levels between cell lines and tumors are shown. Probes were ranked first by significance
(FDR,0.1%) then by magnitude of mean difference between these two groups.
doi:10.1371/journal.pone.0009359.t003
Epigenetics of Ovarian Cancer
PLoS ONE | www.plosone.org 6 February 2010 | Volume 5 | Issue 2 | e9359zero criteria respectively (n=243), KS test p-value ,0.001). We
estimated thatforat least 29%of the 585locimeeting the CpGisland
criteria, increases in methylation were accompanied by decreases in
transcription of the associated gene (Figure 4C). The difference in
correlations in CpG island loci versus non-CpG island loci was not
borne out in the tumor dataset (mean b-values: 20.08 versus 20.10
for loci that met one or more CpG islands criteria versus those that
met zero, KS testp-value=0.052). In tumors, we estimated that for at
least10% of the 492 loci meeting the CpG island criteria, increases in
methylation were accompanied by decreases in transcription of the
associated gene (Figure 4D). We found no consistent relationship
between the distance of a methylation locus from the transcription
start site and the strength of the correlation between its methylation
levels and expression levels of the associated gene (not shown).
Discussion
We quantitatively assessed the DNA methylation status of 1,505
CpG sites, (associated with 808 genes), in 15 commonly used
ovarian cancer cell lines and 27 primary ovarian tumors, 15 serous
(55.5%), 9 endometrioid (33.3%) and 3 clear cell (11.1%). These
proportions roughly reflect the relative frequencies of the different
histologies of ovarian carcinoma diagnosed in the US (serous
tumors 50%, endometrioid 25–30%, mucinous 10–15%, clear cell
5%, and others ,5%) [32].
We found that the DNA methylation profiles of the ovarian
cancer derived cell lines were distinctly different from those of the
primary ovarian tumors. These results are consistent with reports
describing vastly different gene expression patterns between cell
lines and primary tumors in ovarian and other cancers [33–35].
While cell lines can be useful for molecular mechanistic studies,
this study reinforces the need for skepticism in considering them as
models for the cancers from which they originated, both in general
and in the specific case of epigenetic profiling of ovarian cancer.
One notable general difference between cell lines and tumors was
the tendency for DNA methylation measurements to be higher in
the cell lines than in the tumors. These findings are consistent with
reports of an enhanced hypermethylation phenotype in cancer cell
Figure 3. Differential DNA methylation among ovarian tumor histologies. DNA methylation levels are shown for the 90 autosomal CpG sites (68
genes) with a significant difference in methylation between one or more pairs of tumor histologies. Methylation values (b-values) were mean centered for each
gene (across tumors). Data were hierarchically clustered only for the CpG sites. The displayed CpG sites were selected based on the adjusted p-values
associated with differential expression between tumors and cell lines. Red indicates high methylati o nr e l a t i v et ot h es i t e - s p e c i f i cm e a n ,g r e e ni n dicates low
methylation relative to the mean. Rows of data corresponding to sites with the greatest magnitude of difference in methylation levels (b-values) between pairs
of tumor histologiesare labeled(upto 3sitesineach directionfor eachpairwise comparison).S=Serous tumor,E=Endometrioidtumor, CC=Clearcelltumor.
doi:10.1371/journal.pone.0009359.g003
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Gene Symbol Probe ID
Endometrioid- Serous
(mean b)
Endometrioid
(mean b)
Serous
(mean b)
Clear Cell
(mean b)
ENDO . SEROUS
NEFL NEFL_P209_R 0.69 0.90 0.21 0.88
CD40 CD40_P372_R 0.62 0.77 0.15 0.22
DCC DCC_P177_F 0.59 0.68 0.08 0.35
NEFL NEFL_E23_R 0.57 0.80 0.23 0.68
PENK PENK_P447_R 0.56 0.82 0.26 0.78
ADCYAP1 ADCYAP1_P398_F 0.55 0.69 0.14 0.28
LMO2 LMO2_P794_R 0.54 0.98 0.44 0.97
JAK3 JAK3_P156_R 0.53 0.91 0.37 0.77
HTR1B HTR1B_P222_F 0.51 0.74 0.23 0.51
TMEFF2 TPEF_seq_44_S88_R 0.50 0.66 0.16 0.58
DCC DCC_P471_R 0.50 0.64 0.15 0.29
ISL1 ISL1_P379_F 0.49 0.58 0.09 0.06
HPN HPN_P374_R 0.48 0.69 0.21 0.77
ISL1 ISL1_P554_F 0.48 0.54 0.06 0.29
EYA4 EYA4_P794_F 0.48 0.84 0.36 0.69
FGF2 FGF2_P229_F 0.46 0.71 0.25 0.40
TERT TERT_P360_R 0.46 0.72 0.27 0.55
ISL1 ISL1_E87_R 0.45 0.50 0.05 0.07
DLK1 DLK1_E227_R 0.45 0.91 0.46 0.75
THY1 THY1_P149_R 0.45 0.81 0.37 0.67
JAK3 JAK3_E64_F 0.44 0.52 0.08 0.58
ADCYAP1 ADCYAP1_P455_R 0.42 0.53 0.10 0.50
HPN HPN_P823_F 0.40 0.82 0.42 0.98
ZNF264 ZNF264_P397_F 0.37 0.94 0.57 0.63
PRKCDBP PRKCDBP_P352_R 0.37 0.52 0.16 0.44
GUCY2D GUCY2D_E419_R 0.36 0.41 0.04 0.05
FABP3 FABP3_E113_F 0.36 0.41 0.04 0.15
MLF1 MLF1_E243_F 0.29 0.43 0.14 0.17
ADCYAP1 ADCYAP1_E163_R 0.27 0.30 0.02 0.13
PYCARD PYCARD_P150_F 0.22 0.86 0.64 0.73
SPARC SPARC_E50_R 0.21 0.34 0.14 0.33
COMT COMT_E401_F 0.17 0.30 0.13 0.19
THY1 THY1_P20_R 0.16 0.47 0.31 0.50
SEROUS . ENDO
IGF1 IGF1_E394_F 20.49 0.20 0.69 0.41
IGF1 IGF1_P933_F 20.47 0.08 0.55 0.13
SRC SRC_E100_R 20.39 0.54 0.93 0.48
PI3 PI3_P1394_R 20.39 0.39 0.78 0.54
ASB4 ASB4_P52_R 20.38 0.58 0.96 0.88
BLK BLK_P14_F 20.38 0.42 0.80 0.55
JAK3 JAK3_P1075_R 20.38 0.35 0.72 0.75
MOS MOS_P746_F 20.37 0.52 0.89 0.65
FGF7 FGF7_P44_F 20.34 0.56 0.90 0.60
PECAM1 PECAM1_E32_R 20.33 0.58 0.91 0.58
NOTCH4 NOTCH4_P938_F 20.31 0.53 0.84 0.79
P2RX7 P2RX7_P597_F 20.28 0.68 0.97 0.99
SERPINA5 SERPINA5_E69_F 20.27 0.58 0.85 0.68
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One prior study of ovarian cancer found fewer hypermethylated
CpG islands in cell lines versus primary tumors [37]. Our results
do not support this finding. Because the methylation sites
represented in the arrays used for this study were biased towards
sites known to be methylated in some cancers, this finding may be
consequence of the fact that cell lines represent a ‘pure’ culture of
cancerous cells whereas the primary tumors inevitably contained a
mixture of tumor cells and other cells. This ‘normal contamina-
tion’ effect is supported by our finding that nearly all of the CpG
sites that showed higher methylation in tumors than in cell lines
also had elevated levels of DNA methylation in leukocytes from
healthy women. Accumulation of epigenetic changes during
prolonged cell culture may also contribute to the higher frequency
of hypermethylation in the cell lines. This was observed for cancer
cell lines [36], as well as hES cell lines and their derivatives
[38,39]. Furthermore, DNA methylation profiles of the hESC-
derived neural precursor cells [38,39] and hESC-derived liver cells
[40] were shown to be different from their in vivo derived
counterparts.
Although the numbers of some subtypes, such as clear cell
tumors, were small, unsupervised and supervised analyses of the
DNA methylation profiles of the primary tumors indicate clear
differences between the histological types. We identified 90 CpG
Gene Symbol Probe ID
Endometrioid- Serous
(mean b)
Endometrioid
(mean b)
Serous
(mean b)
Clear Cell
(mean b)
DNAJC15 DNAJC15_P65_F 20.26 0.71 0.98 0.63
ASB4 ASB4_E89_F 20.25 0.70 0.96 0.89
RARA RARA_P1076_R 20.19 0.72 0.91 0.85
AGXT AGXT_P180_F 20.17 0.81 0.97 0.72
SRC SRC_P164_F 20.14 0.81 0.96 0.75
ABCC2 ABCC2_P88_F 20.14 0.85 0.98 0.74
CpG sites with the most significant differences in DNA methylation levels are shown for the pair-wise comparisons between endometrioid and serous tumors. Probes
were first ranked by significance then by magnitude of mean difference between groups.
doi:10.1371/journal.pone.0009359.t004
Table 4. Cont.
Table 5. Loci with differential methylation between clear cell versus serous tumors (FDR,1%).
Gene Symbol Probe ID
Clear Cell – Serous
(mean b)
Clear Cell
(mean b)
Serous
(mean b)
Endometrioid
(mean b)
CC . SEROUS
NEFL NEFL_P209_R 0.66 0.88 0.21 0.90
TCF4 TCF4_P317_F 0.60 0.70 0.09 0.25
WT1 WT1_P853_F 0.58 0.64 0.07 0.21
HPN HPN_P374_R 0.57 0.77 0.21 0.69
PYCARD PYCARD_E87_F 0.57 0.59 0.03 0.04
FGFR3 FGFR3_P1152_R 0.55 0.74 0.19 0.26
P2RX7 P2RX7_P119_R 0.54 0.68 0.14 0.15
TNFSF10 TNFSF10_P2_R 0.51 0.64 0.12 0.03
CCND2 CCND2_P887_F 0.45 0.50 0.05 0.15
CEBPA CEBPA_P1163_R 0.43 0.49 0.05 0.05
CCND2 CCND2_P898_R 0.40 0.45 0.05 0.28
GSTM2 GSTM2_E153_F 0.39 0.45 0.06 0.34
SPDEF SPDEF_E116_R 0.34 0.46 0.12 0.08
NTSR1 NTSR1_P318_F 0.32 0.40 0.08 0.44
MCC MCC_P196_R 0.27 0.27 0.01 0.28
HLA-DRA HLA-DRA_P77_R 0.24 0.30 0.07 0.19
GP1BB GP1BB_E23_F 0.21 0.30 0.10 0.09
SEROUS . CC
SRC SRC_E100_R 20.45 0.48 0.93 0.54
PECAM1 PECAM1_E32_R 20.33 0.58 0.91 0.58
CpG sites with the most significant differences in DNA methylation levels are shown for pair-wise comparisons between clear cell and serous tumors. Probes were first
ranked by significance then by magnitude of mean difference between groups.
doi:10.1371/journal.pone.0009359.t005
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methylation patterns, the majority of which distinguished serous
from endometrioid tumors. The distinctness of the DNA
methylation profiles of the histological subtypes is suggestive of
different tumorigenic mechanisms and/or cells of origin and
underscores the need to view the different histological types of
ovarian cancer as different diseases. While this notion is common
knowledge among clinicians, and is reflected in studies of tumor
gene expression [41] and protein expression [42], regrettably, it is
often ignored in molecular diagnostic studies, and all cases of
ovarian cancer are still treated similarly in clinic despite their
acknowledged differences in pathology. Successful detection and
treatment strategies for ovarian cancer are likely to be histology-
specific, and will require a better understanding of the biological
characteristics of each subtype.
Asone ofthelargest studiestoexamine correlationsbetween gene
expression and DNA methylation, our results in this regard are
noteworthy. We found for some genes that increased DNA
methylation was correlated with decreased levels of transcription
of the associated gene, but that there were also many genes for
which such a relationship was not evident. We estimated that
increases in methylation levels were associated with decreases in
transcription of the corresponding gene for 27% of the 828 CpG
sites with variable DNA methylation across 15 ovarian cancer cell
lines (Figure 4A). Among loci in CpG islands, we estimated that
increases in DNA methylation were accompanied by decreases in
transcriptionofthe associatedgeneforatleast29%of585CpGsites
across cell lines (Figure 4C). Across all CpGs and CpG island loci,
the association between DNA methylation and gene expression was
much stronger among the cell lines than among the primary tumor
tissues, most likely due to the confounding effect of cellular
heterogeneity in the tumor specimens. Our findings are consistent
with a recent study of large B-cell lymphoma [43], in which a wide
range of correlations between gene expression and methylation
were reported. Interestingly, all three of the genes evaluated in this
study that were highlighted in the previous study as having a strong
correlation between hypermethylation and expression showed a
similar negative correlation in our cell line dataset (MGMT: 20.63,
RBP1: 20.78, IGSF4: 20.69). Our results support the generality of
the recognized relationship between promoter CpG island hyper-
methylation and gene silencing. However, the fact that this inverse
relationship was not observed for the majority of loci, similar to
another report [43], further highlights the complexity of this
relationship.
The data presented here provide a first glimpse of the extent of
variation in levels of DNA methylation among ovarian cancer
specimens and as such provide a useful new lens through which to
examine their defining characteristics. In principal, DNA methyl-
ation profiling could also be useful for discovery of biomarkers for
detection of ovarian cancer, based on assays using sensitive PCR-
based approaches for detection of methylated DNA [44–51].
However, even if we can identify a DNA-methylation marker that
distinguishes tumors from normal cells with high sensitivity and
specificity, additional criteria would need to be satisfied in order for
this approach to be viable: adequate quantities of tumor-derived
DNA would need to reach and persist in an assayable fluid (like
blood or proximal fluids) in women with occult ovarian cancers still
at a curable stage, and the abundance of the specifically methylated
DNA sequences in fluids from these women would need to
significantly exceed background levels in cancer-free individuals.
These criteria seem difficult to satisfy in a blood-based early
detection test for ovarian cancer, given the small size of the tumors
that we need to detect [52,53]. To this end, and as a primary step,
we compared the DNA methylation profiles of normal leukocytes
and ovarian tumors. But the potential of DNA methylation markers
as early-detection markers using proximal fluids or for detection of
recurrent cancer in a blood-based assay remains to be evaluated.
Additional profiling of primary tumors and corresponding normal
tissues (fallopian tube, ovarian surface epithelium, peritoneum or
endometrium) as well as measurements of methylated DNA in
candidate detection media (blood or proximal fluids) in both health
and disease will help define the natural history of ovarian cancers
and critically assess the potential utility of DNA methylation based
biomarkers in combating ovarian cancer.
Materials and Methods
Sample Collection and Processing
Ovarian tumors. Tumor tissues were obtained from patients
with informed consent, which was approved by the Institutional
Table 6. Loci with differential methylation between clear cell versus endometrioid tumors (FDR,5%).
Gene Symbol Probe ID
Clear Cell -
Endometrioid (mean b)
Clear Cell
(mean b)
Endometrioid
(mean b)
Serous
(mean b)
TRIP6 TRIP6_P1090_F 0.71 0.91 0.20 0.31
TRIP6 TRIP6_P1274_R 0.62 0.80 0.18 0.30
TNFSF10 TNFSF10_P2_R 0.60 0.64 0.03 0.12
IL1RN IL1RN_P93_R 0.58 0.87 0.29 0.32
THBS2 THBS2_P605_R 0.54 0.62 0.08 0.21
P2RX7 P2RX7_P119_R 0.53 0.68 0.15 0.14
CEBPA CEBPA_P1163_R 0.44 0.49 0.05 0.05
SPDEF SPDEF_E116_R 0.38 0.46 0.08 0.12
HOXC6 HOXC6_P585_R 0.38 0.51 0.13 0.21
ESR1 ESR1_P151_R 0.36 0.43 0.07 0.15
SPDEF SPDEF_P6_R 0.33 0.45 0.12 0.25
GP1BB GP1BB_E23_F 0.21 0.30 0.09 0.10
CpG sites with the most significant differences in DNA methylation levels are shown for pair-wise comparisons between clear cell and endometrioid tumors. Probes
were first ranked by significance then by magnitude of mean difference between groups.
doi:10.1371/journal.pone.0009359.t006
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acquisition, processing and storage were conducted by the
Pacific Ovarian Cancer Research Consortium (POCRC) at the
Fred Hutchinson Cancer Research Center. The quality of tumor
tissues, the percentage of cancer cells and the histological analysis
of the tumors were determined via a centralized pathology review
at the POCRC repository. All samples were distributed in a de-
identified manner and cannot be traced back to patients. Tumor
and patient characteristics are summarized in Table 1.
Cell lines. The sources and characteristics of the 15 ovarian
cancer-derived cell lines analyzed are summarized in Table 2. All
cell lines were cultured according to the specifications outlined by
ATCC. Cell lines were grown to 80% confluence, then serum-
deprived in 0.5% FBS for 24 hours before harvesting. Cells were
washed twice with Hank’s Balanced Salt Solution (Invitrogen,
Carlsbad, California) and drained. 1 mL of SDS extraction buffer
(0.1M NaCl, 20 mM Trizma base, 25 mM EDTA, 0.5% w/v
SDS) was added directly to the plate to lyse the cells. Cellular
lysate was scraped off the plates, pipetted into a cryovial, and
stored at 280uC until DNA extraction. Lysates were treated with
200 ug/ml ProteinaseK at 50uC overnight. DNA was precipitated
with one volume of Isopropanol and dissolved in TE
24 buffer.
Buffy coat. Whole blood from two females (age.60) was
purchased from HemaCare Corporation. Blood was collected in
anticoagulant containing blood collection bags and kept on ice.
Samples were processed immediately upon receipt.
DNA and RNA extraction from ovarian tumors. The
tumor tissues were disrupted in a Biospec Tissue-Tearor Model
Figure 4. Correlations between DNA methylation and gene expression levels. The distributions of Spearman correlations between DNA
methylation levels (b-values) and gene expression levels [log2(sample/reference)]. Cell lines and tumors were analyzed separately and was restricted
to autosomal CpG sites with variable DNA methylation levels across the relevant specimen set and a minimum number of non-missing values (see
Methods). A) Cell lines: Density plots of observed and simulated Spearman correlations for all filtered loci. N=828 CpG sites (502 genes); B) Tumors:
Density plots of observed and simulated Spearman correlations for all filtered loci. N=758 CpG sites (482 genes); C) Cell Lines: Density plot of
observed and simulated Spearman correlations for loci meeting CpG island criteria. N=585; D) Tumors: Density plot of observed and simulated
Spearman correlations for loci meeting CpG island criteria. N=492.
doi:10.1371/journal.pone.0009359.g004
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PLoS ONE | www.plosone.org 11 February 2010 | Volume 5 | Issue 2 | e9359Figure 5. Top correlations between DNA methylation and gene expression. The 8 CpG sites with the most negative correlations between
DNA methylation and gene expression levels are shown for each of the two specimen sets: A) Cell lines; B) Tumors.
doi:10.1371/journal.pone.0009359.g005
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10 ml TRIzol per 50 mg of tissue. Following an extraction step of
0.2 ml of Chloroform per 1 ml of TRIzol, the upper aqueous
phase was removed for RNA isolation. The remaining inter-phase
and the phenol phase was briefly stored in 4uC for DNA isolation.
The upper aqueous phase was processed for total RNA according
to Invitrogen protocol and further purified using RNeasy Mini kit
(Qiagen). Genomic DNA was isolated by back-extraction from the
TRIzol inter-phase and the phenol phase as described on Ambion
website (page 4) [54]. Detailed amplification and labeling protocols
are available at the Brown lab website [55].
DNA extraction from buffy coat. Blood samples were
centrifuged for 10 min at 300 g in 50 ml conical tubes, followed by
another 10 min centrifugation at 1,600 g. Buffy coat was isolated
and DNA was extracted using Qiagen QIAamp DNA Blood Kit
and stored in 230 C until sodium bisulfite conversion.
RNA extraction from ovarian cell lines. Cell lines were
lysed in Phenol followed by a Phenol/Chloroform extraction. The
aqueous layer was added to 70% ethanol and further purified by
loading the RNA/Ethanol mix into an RNeasy Mini kit (Qiagen)
column. Purification was continued and finalized as described in
the RNeasy kit (Qiagen) Manual. Detailed amplification and
labeling protocols are available at the Brown lab website [55].
DNA Methylation Analysis
DNA methylation assay platform. DNA methylation
analysis was performed using Illumina’s Golden Gate Cancer
Panel 1 bead array [16]. These arrays contain DNA probes
representing 1505 CpG islands near 808 genes. Probes were
selected for cancer-related genes based on data from Illumina’s
scientific collaborators, literature, and public databases.
Experimental methods. Briefly, genomic DNA from 27
primary ovarian tumors and 15 ovarian cell lines was subject to
sodium bisulfite conversion, labeled with fluorescent dyes, and
hybridized to Illumina Golden Gate Cancer Panel 1 bead arrays at
the University of Southern California Epigenome Center. We
utilized a number of DNA methylation control reactions to assess
the extent of bisulfile conversion completion as explained in detail
elsewhere [56]. Methods and reagents for sodium bisulfite
conversion and array hybridizations were as previously described
[8,16,57].
Data processing. DNA methylation values from the bead
array hybridizations were scored as b-values [16]. b-values for
each probe in each experiment were calculated as the ratio of the
methylated signal over the total fluorescent signal on a scale
between 0 and 1 [16]. b-values thus indicate a locus’ observed
methylation relative to the maximum potential methylation of that
site. For quality control, we obtained non-background corrected
signal intensities of the methylated (M) and unmethylated (U)
probes and the mean negative control cy5 (red) and cy3 (green)
signal intensities. We also obtained the Detection p-values, which
provide an indication of DNA methylation measurement quality
for each locus and are calculated based on the difference in signal
intensity of each probe compared to the set of negative control
probes. Measurements for which the detection p-value is less than
0.05 are considered to have a signal intensity significantly above
background. Data points with a detection p-value.0.05 are
masked as ‘‘NA’’, and represent beta values with non-significant
detection of DNA methylation compared to background.
Gene Expression Analysis
Assay platform. We measured transcript levels in the 27
primary ovarian tumors and 15 cell lines using the HEEBO [16]
oligonucleotide microarrays, containing 44,544 70-mer probes
and printed at the Stanford Functional Genomics Facility.
Detailed information on the HEEBO arrays is available at the
Stanford Functional Genomics Facility website [25].
Experimental methods. Microarray experiments were
performed as described at the Brown lab website [58]. Briefly,
500 mg of total RNA from each of the ovarian tumors were
amplified using Amino Allyl Message Amp
TM II aRNA Kit
(Ambion, Austin, TX, USA). The aRNAs were labeled with Cy5
and co-hybridized with Cy3 labeled Stratagene reference aRNA.
For some samples, the mRNA was amplified and hybridized in
duplicate or triplicate. The samples were then hybridized to
HEEBO microarrays. The arrays were scanned in a low-ozone
environment using a GenePix 4000A microarray scanner and
images were analyzed with Genepix 5.0 (Axon instruments, Union
City, CA). The raw data were deposited into Stanford Microarray
Database [59] and can be viewed at the SMD website [60].
Data processing. 1) By Spot: A spot quality filter was
applied to every spot on each array. Only spots with a Cy5/Cy3
ratio of intensity/background .1.5 in either channel were
included. Spots that were flagged manually for poor quality by
visual inspection of spot uniformity were excluded. The log (base2)
of Cy5/Cy3 normalized ratio (mean) was calculated for each spot.
Ratios were normalized for each array such that the distribution of
log ratios for the array had a mean of 0.0. Empty and control spots
were dropped after normalization. Spots with the same Entrez
Gene ID were averaged. 2) By Array: Replicate hybridizations of
the same amplified mRNA were averaged by Entrez Gene ID.
Hybridizations of independent amplifications of the same sample
mRNA were averaged by Entrez Gene ID.
Statistical Methods
DNA methylation clustering and visualization. To
visualize the DNA methylation patterns across all ovarian cancer
cell lines and tumors, we first filtered for genes with some variation
across the sample set. Specifically, we restricted our analysis to
CpG sites with minimum b-value greater than 0.2, ratio of
maximum b-value to minimum b-value greater than or equal to 2
and 1 or fewer missing b-values. We then mean-centered the
selected 1184 b-values by gene and applied two-way average-
linkage unsupervised hierarchical clustering on the resulting data.
Note that while this data are filtered, no comparisons were made
and data were clustered for both samples and CpG sites. We
visualized the clusters in Java Treeview [61,62].
Identification of loci with biopecimen-specific DNA
methylation levels (cell line versus tumor). To identify loci
that showed significantly different levels of DNA methylation in
cell lines versus tumors, we first restricted our analysis to the 1,110
autosomal CpG sites whose b-values were variable across the set of
15 cell lines and 27 tumors. We defined variable CpG sites as those
CpG sites with minimum b-value greater than 0.2, ratio of
maximum b-value to minimum b-value greater than or equal to 2
and 1 or fewer missing b-values. We then performed a two-sample
t-test comparing the 15 cell lines to the 27 tumors. P-values from
the t-test were adjusted for multiple comparisons by controlling the
false discovery rate [23]. All statistical analyses were performed
using the R software package [63].
Identification of loci with histological subtype-specific
DNA methylation levels. To identify ovarian cancer subtype-
specific loci, we first restricted our analysis to the 818 autosomal
CpG sites whose b-values were variable among the 27 primary
tumors. We defined variable CpG sites as those CpG sites with
minimum b-value greater than 0.2, ratio of maximum b-value to
minimum b-value greater than or equal to 2 and 1 or fewer
missing b-values. We performed pair-wise two-sample t-tests
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(serous vs. endometrioid, serous vs. clear cell, endometrioid vs.
clear cell). P-values from each pair-wise analysis were adjusted for
multiple comparisons by controlling the false discovery rate [23].
All statistical analyses were performed using the R software
package [63].
Association of DNA methylation and gene expression.
We paired loci used in methylation analysis with gene expression
data from the appropriate loci according to Entrez Gene ID. For
gene expression data, we used the normalized log ratios of Cy5/
Cy3 (see Microarray methods). For DNA methylation, normalized
b-values were used. We excluded X-linked loci from this analysis
because of the X-chromosome associated dosage compensation
mechanisms could cause a decoupling of methylation levels and
gene expression levels. We further restricted our analysis to loci
with at least 5 (of 15) non-missing gene expression measurements
in the cell line analysis and 9 (of 27) non-missing gene expression
measurements in the tumor analysis. For the 758 CpG sites that
were sufficiently variable across all tumor specimens (see filtering
above), we calculated the Spearman correlation between DNA
methylation levels and gene expression levels. Similarly, we
calculated Spearman correlations for the 828 CpG sites that
were sufficiently variable across all cell line samples (see filtering
above). For each dataset, the false discovery rate was estimated by
calculating the median number of loci with correlations below a
given threshold over 500 permutations of the gene labels. All
statistical analyses were performed using the R software package
[63].
Supporting Information
File S1 Methylation array probe annotations and associated
methylation and gene expression data. List of probes and
associated annotations (locus, gene, distance from transcription
start, etc) for the Illumina bead array used to profile specimens.
Observed methylation values (b-values) for each probe and
specimen are recorded as are the gene expression levels (log base2
ratio) of the associated transcripts.
Found at: doi:10.1371/journal.pone.0009359.s001 (2.20 MB
XLS)
File S2 Loci with differential DNA methylation. List of CpG
sites with significant differences in DNA methylation between cell
lines and tumors or between tumor histologies. Associated probe
data are also included.
Found at: doi:10.1371/journal.pone.0009359.s002 (0.40 MB
XLS)
File S3 CpG island information and distance from the
transcription start site of probes with differential methylation
between tumor histologies.
Found at: doi:10.1371/journal.pone.0009359.s003 (0.06 MB
XLS)
Figure S1 Correlation in DNA methylation values between pairs
of probes. The distribution of Pearson correlations is shown for i)
pairs of related probes (2 CpG sites, 1 gene) ii) pairs of unrelated
probes (2 CpG sites, 2 genes). For related probes, only the 1184
probes (686 genes) which exhibited sufficient variation across the
42 specimens (see Methods) were included.
Found at: doi:10.1371/journal.pone.0009359.s004 (0.36 MB TIF)
Figure S2 Correlation matrix for DNA methylation values
across loci. Pearson correlations in methylation values for pairs of
CpG sites are shown colorimetrically. CpG sites are sorted by their
location in the genome. The 1,184 CpG sites (686 genes) selected
for variation in methylation across all specimens were used
(Figure 1). Correlation calculations were based on 42 specimens.
Red indicates positive correlation, green indicates negative
correlation.
Found at: doi:10.1371/journal.pone.0009359.s005 (5.37 MB
PDF)
Figure S3 Overlap between tumor histology lists. A) Venn
diagram showing number of CpG sites in each histology-specific
list and overlap between lists; B) Venn diagram showing number of
genes in each histology-specific list and overlap between lists.
S=Serous tumor, E=Endometrioid tumor, CC=Clear cell
tumor.
Found at: doi:10.1371/journal.pone.0009359.s006 (0.13 MB TIF)
Figure S4 Methylation-gene expression correlation across cell
lines versus methylation-gene expression correlation across
tumors.
Found at: doi:10.1371/journal.pone.0009359.s007 (0.17 MB TIF)
Appendix S1 Pacific Ovarian Cancer Research Consortium
Menopausal Determination
Found at: doi:10.1371/journal.pone.0009359.s008 (0.02 MB
DOC)
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